about to start next upwards move, page-2

Psychiatric and neurological disorders constitute as much as 35% of the disease burden in the seven major pharmaceutical markets, representing continuing opportunities for pharma companies in the CNS market. However, the increasing presence of generic products coupled with low levels of innovative launches has resulted in a slowdown in market growth and considerable unmet need across the spectrum of CNS disorders.

Hence and praise the arrival of SOLAGRAN........

The CNS Market Outlook to 2011 provides comprehensive epidemiological analysis of the major CNS indications and key factors impacting market and competitive dynamics.

Evaluate changes in the competitive positions of the leading companies in the CNS market and ensure your R&D pipeline is aligned with future market opportunity to maximize commercial success.

Alzheimer's disease is forecast to be the primary growth driver in the CNS market over the forecast period, with a CAGR estimated at 10.3% for 2005-11. This growth is attributed to the arrival of new products and the implementation of successful strategies by major pharmaceutical companies to protect existing revenue streams.

Of the most promising compounds identified, five are replacement compounds for blockbusters that have or are forecast to lose patent protection over the forecast period to 2011. Such products include J&Js paliperidone, Lillys Symbyax, Pfizers Lyrica, and Wyeths DVS-233.

Solagran Ltd., of Melbourne, Australia, entered a preliminary agreement to acquire a 60 percent interest in a plant-based extract manufacturer ? SibEX, of Tomsk, Russia. The proposed deal would enable Solagran to increase its production capacity of its liver disease drug Ropren by a factor of 10, sufficient to meet expected market demand once the product receives Russian regulatory approval. Ropren, which is made from Bioeffective R, one of 15 Bioeffectives that Solagran has developed, also has completed clinical trials in Russia for neurodegenerative disorders such as Alzheimer?s disease.

Glad I have a few now how about everyone else? More news soon, up we go.